During the 2015-16 winter, the US experienced a relatively mild influenza season compared to Taiwan 40 which had a large number of total and severe cases. While H1N1pdm viruses dominated global 41 surveillance efforts in this season, the global distribution of genetic variants and the contribution of 42 genetic to disease severity has not been investigated. Nasal samples collected from influenza A positive 43 patients by the Johns
Diagnosis and subtyping 126
Nasopharyngeal swabs or nasal washes of patients collected at the time of enrollment were tested for 127 influenza A virus infection using the Cepheid Xpert Flu/RSV test (Cepheid, Sunnyvale, CA) . Samples that 128 were influenza A virus positive were further subtyped by qRT-PCR with specific H1 or H3 primers and 129 probes according to USA Centers for Disease Control and Prevention (CDC) protocols. Only H1N1 130 positive samples were moved on to whole genome sequencing analysis. 131 132 Whole genome sequencing (WGS) 133 Viral RNA was isolated from the influenza A positive clinical samples using the MagMax Viral RNA 134 isolation reagent (Thermo Fisher) on an Eppendorf epMotion 5073 liquid handling workstation. Samples 135 were processed for whole genome sequencing using multi-segment PCR [9] and then prepared for deep 136 sequencing using the Nextera XT library preparation reagent (Illumina). Samples were sequenced on the 137 Illumina NextSeq platform. Raw paired-end data were first processed through Trim galore! with a quality 138 score of 30 and an adapter sequence of CTGTCTCTTATACACATCT, only retaining pairs that both passed 139 through this quality control step. The quality-trimmed reads were then aligned to the influenza vaccine 140 strain reference sequence using bowtie2 (version 2.1.0) with the '--very-sensitive-local' option and 141 converted to sorted BAM files using samtools. Only sequences of all 8 gene segments passed quality 142 controls were included in the study. The sequences were submitted to NCBI GenBank database. The 143 accession numbers are listed in the Table S1 . 144 145 Phylogenetics and sequence analysis 146 73 H1N1pdm clinical samples which yielded sufficient WGS coverage of the IAV genome were included 147 in sequence analysis. In addition to these genomes, we retrieved two reference genomes of vaccine 148 strains from the Global Initiative on Sharing All Influenza Data (GISAID, https://www.gisaid.org/) for 149 further analyses. Nucleotide sequences of the longest open reading frames (ORFs) in each gene segment 150 were used to build phylogenetic trees, including PB2, PB1, PA, HA, NP, NA, M1, and NS1, as well as, their 151 alternative splicing (M2 and NS2) and ribosomal frameshift (PA-X) produces. Nucleotide sequences of 152 these ORFs (except for PA-X) in each strain were further concatenated to generate one single sequence 153 for constructing a whole-genome phylogenetic tree. Phylogenetic trees for investigating their genetic or 154 genomic relationships were based on maximum likelihood (ML) analysis, generated by using RAxML 155 (version 8.2.12) [10] under GTRGAMMA model with a bootstrap value of 1000. Their time scales based 156 on sample collection dates were calibrated using TreeTime [11] after building ML trees. 6B clade, and 6B.1, and 6B.2 subclades were defined by the rules of HA amino acid substitutions of global surveillance 158 groups from nextflu (https://github.com/blab/nextflu). Phylogenetic groups in other gene segments 159 were based on their tree branches to separate annotated clades (e.g., 6B.1 and 6B.2). Inconsistent 160 positioning of strains, or clade groups on individual trees was used to identify influenza reassortment. 161
Eventually, individual gene segment clades were annotated and visualized using the ggtree R package 162 [12] . 163 164 To investigate the genetic groups in public database, all H1N1pdm genomes (n=2873) isolated from 165
September, 2015 to May, 2016 were downloaded from GISAID as of January 2020, and were further 166 aligned using MAFFT tool [13] under the default conditions. Moreover, we retrieved all NP sequences 167 (n=20,477) of H1N1pdm isolated after the year of 2009 (inclusive) from GISAID as of January 2020 to 168 investigate the population of early start codon of NP gene. 20,470 NP sequences were used for further 169 analyses, after aligning and removing 77 sequences with unexpected insertions. 170
Glycosylation prediction 172
Potential N-linked glycosylation sites of the 6B.1 and 6B.2 HA and NA proteins were predicted by the 173 NetNGlyc 1.0 server (http://www.cbs.dtu.dk/services/NetNGlyc) to show any changes compared to the 174 vaccine A/California/7/2009. 175 176
Statistical analysis of demographic and clinical data 177
To identify a contribution of virus clades and genetic subgroups to clinical symptoms, we applied Chi-178 square or Fisher's exact tests for categorical variables and the rank-sum test for continuous variables 179 when appropriate. The two-tailed statistical significance was set at p-value <0.05. When clinical or 180 demographic category reached statistical significance in a univariate analysis, confounding effects were 181 then analyzed. In addition to adjusting for possible confounding effects between demographics, disease 182 severity and clinical outcomes, a propensity score-based weighting was applied. Briefly, we applied 183 those potential confounders to generate the propensity (or probability) of being infected with different 184 subgroups of H1N1pdm viruses by using machine learning based modeling methods [14] . By using the 185 inverse probability of treatment weighting (IPTW) method, patients with higher propensity will have 186 lower weights in the final logistic regression model to adjust for confounding factors. The weights create 187 a pseudo-population where the weighted virus subgroups have similar distribution across these 188 confounders. In one simulation model, the propensity score-based weighting methods could adjust for 189 most of the confounding effects [15] 
Full-length genome analysis and additional genetic differences between clades 6B.1 and 6B.2. 220
Phylogenetic analysis of 10 open reading frames (ORFs) from the other seven gene segments were also 221 analyzed ( Figure S1 ). Branch tips were colored by the HA clade of each sample and defining amino acid 222 substitutions were noted. For the most part, the sequences of other ORFs clustered together consistent 223 with their HA clade. Fifteen amino acid differences were identified on the other 8 viral ORFs between 224 6B.1 and 6B.2 viruses (Table 1) . Two amino acids K299R (K in 6B.1 and R in 6B.2) and T453P on PB2 were 225 different ( Figure S1A ). One amino acid K361R on PA was different ( Figure S1C ). One amino acid A212V 226 on PA-X was different ( Figure S1D ). One amino acid A6V on NP was different ( Figure S1F ). Five amino 227 acid I13V, V34I, V67I, M314I and T381I on NA were different ( Figure S1G ). One amino acid K208Q on M1 228 was different ( Figure S1H ). Two amino acids E2D and D125E on NS1 were different ( Figure S1J ). Two 229 amino acids E2D and I83M on NS2 were different ( Figure S1K ). 230
231
As for the 6B viruses, all segments of two of the four 6B viruses, A/EastBaltimore/0103/2016 and 232 A/Baltimore/0088/2016, were 6B lineage. One 6B virus A/Taipei/0045/2016 contained PB2, PA, NA and 233 M segments from 6B.1 lineage and the rest segments were 6B but more similar to 6B.1 than 6B.2. The 234 other 6B virus A/Linkou/0030/2015 contained PB2 and NS segments of 6B.2 lineage and the rest 235 segments were 6B but more similar to 6B.2 than 6B.1 (Figure 2 and S1). These suggested that every 236 segment of 6B virus which once evolved was either toward to 6B.1 lineage or 6B.2 lineage. 237 238
Early start codon of nucleoprotein (NP) 239
The NP gene segments of all samples have an early start codon 18 nt upstream of the start codon of 240 human seasonal H1N1 and H3N2. This start codon were utilized and obtained polymerase activity [18, 241 19 ]. All the NP proteins could have an additional 6 amino acids at their amino terminus, with clade 6B.1 242 (MSDIEA) and 6B.2 viruses (MSDIEV) differing at amino acid six. The presence of an upstream NP start 243 codon and the difference between 6B.1 and 6B.2 were also present in virus sequences available in 244 GISAID. Approximately 70% of publish sequences (n=20,470) of H1N1pdm NP since 2009 have this early 245 start codon and the amino acid six were mostly Alanine, and 24% (n=4924) without genetic data 246 including A/California/7/2009 in this region may be due to manually trimmed for sequence submission. To better understand subgroup genetic diversity in the identified HA clades, we performed a 284 phylogenetic analysis using concatenated gene segments ( Figure 2 ). Each gene from the 6B.1 or 6B.2 285 lineages, which may or may not be the same as its HA clade, was determined by individual ORF tree 286 ( Figure S1 ) and listed on the right of the concatenated gene segment phylogenetic tree ( Figure 2 ). Four 287 distinct virus genetic subgroups were present in this dataset ( Figure 2 and Table 1 ). 6B.1 viruses were 288 separated into two groups; one defined by two substitutions (NA-F74L and NS2-G22V) which we refer to 289 as 6B.1 variant virus compared to viruses without these substitutions, which we refer to as 6B.1 parental 290 virus. All Baltimore 6B.1 viruses were 6B.1 parental. In Taipei, only 4 were 6B.1 parental, with the 291 remaining clade 6B.1 viruses (23/27) being 6B.1 variant. 292
293
The 6B.2 viruses were also separated into two genetic subgroups with 6 viruses (identified with the HA-294 A261S mutation) named 6B.2 variant-1 and 13 viruses (defined by four substitutions: NA-S52R and -295 G96S, M1-S30N and M2-Y52C) named 6B.2 variant-2 virus. 296 297
Demographic and clinical analysis based on virus genetics 298
The demographic and clinical data from patients infected with clade 6B.1 or 6B.2 viruses were first 299 compared by univariate analyses (Table 2 ). There were no 6B.2 viruses at the Baltimore sites. Patients 300 infected with 6B.2 were more likely to be older, female, Asian, and unvaccinated. These patients had a 301 higher prevalence of runny nose and diarrhea and had increased symptoms of severe influenza, 302
including increased likelihood of oxygen supplementation, longer in-hospital stay, and pneumonia 303 diagnosis (by radiological findings) (p=0.05). Interestingly, patients infected with clade 6B.1 viruses had a 304 lower number of co-morbidities associated with severe influenza, suggesting a healthier population was 305 being infected with those viruses. 306
307
We further utilized a logistic regression analysis to estimate the propensity of being infected by 6B.2, 308 using potential confounders such as age, gender, comorbidities, obesity, vaccine status, human 309 exposure and travel history (area under the ROC curve: 0.798). After inverse probability of treatment 310 weighting (IPTW) to adjust for the possible confounding effects, infection with clade 6B.2 viruses was 311 found to be significantly associated with pneumonia (Odds ratio: 3.261, 95% CI: 1.696-4.826, p=0.008) 312 (Table 3) . 313
The distribution of cases across the four H1N1 genetic subgroups was then determined (Tables 4 and 5) . 315
When patients infected with the 6B.1 parental or variant viruses were compared (Table 4) , more 316 patients infected with 6B.1 parental were from Baltimore and all the 6B.1 variant-infected patients were 317 from Taipei. Patients infected with the 6B.1 parental viruses reported having increased wheezing, sinus 318 pain, and nausea/vomiting. There were no differences between the two 6B.1 subgroups with respect to 319 severe symptoms. When patients infected with the 6B.2 variant-1 and variant-2 viruses were compared 320 there were no obvious difference in symptoms ( reported that the circulating H1N1pdm strain in 2015-16 were antigenically similar to the vaccine 360 A/California/7/2009 in the US, UK and many other countries [1, 5, 6, 27, 37, 38] (manuscript in 361 preparation). This suggests that the HA amino acid differences between the circulating 6B.1 or 6B.2 362 clade viruses and the vaccine strain were likely not able to explain differential epidemics in different 363 regions of the year even though vaccination coverage might differ in different regions. Whether 364 mutations in the other 7 viral genes contributed to the variable disease severity reported in 2015-16 has 365 not been studied carefully. 366
367
Only a few studies reported full genome sequences of the 2015-16 circulating H1N1pdm strains. Fifty-368 five isolates and 22 clinical samples in Russia, 5 virus isolates in eastern India, and 2 viruses in Bulgaria 369 were whole-genome sequenced and reported [6, 38, 39] , all of which were clade 6B.1 viruses. In the 370 GISAID database, 6B.2 viruses circulated mainly in Asia, primarily in Japan, Singapore, Indonesia, Taiwan, 371
and Shanghai (China). However, clade 6B.2 viruses were also identified in the USA, England, Scotland, 372
France, Denmark, Norway, Ukraine, Australia and Brazil, albeit in very low numbers. In the 2015-16 373 season, only 126 whole genome sequences of clade 6B.2 viruses were present according to 2873 374
H1N1pdm whole genomes retrieved from GISAID as of January, 2020. Despite the genome sequence 375 differences between the circulating H1N1pdm 6B.1 and 6B.2 strains and the vaccine strain, the 376 relationship of the viral whole genome sequences with disease outcome has not yet been investigated. 377
Our surveillance in Baltimore, USA and Taipei, Taiwan led to the identification and sequencing of both 379 6B.1 and 6B.2 viruses in the 2015-16 year. 6B.1 and 6B.2 have 7 amino acid differences on HA and 15 380 amino acid differences in the other 8 viral proteins, along with a larger number of synonymous 381 mutations. The data revealed that not only did the HA gene evolve significantly during the 2015-16 year 382 but the other 7 genes also accumulated mutations to form distinct genetic subgroups (Figure 2 and S1). 383
We hypothesized the two viral strains may relate to differential disease outcome and infection with 6B.2 384 was associated with increased disease symptoms. The only report for symptoms of 6B.1 and 6B.2 385 infection was seen in Israel, where infection with 6B.2 virus was associated with more vomiting and 386 nausea compared to 6B.1-infected patients [30] . In our surveillance, we did see higher percentage of 387 6B.2 than 6B.1 patients with vomiting and nausea, but this did not reach statistical significance (Table 2) . 388
There was increased reports of runny nose and diarrhea in patients infected with 6B.2 compared to 6B.1 389 in our study. Reporting symptoms may be subjective. Hence, we considered disease severity using more 390 objective criteria, such as oxygen supplementation, intubation, pneumonia, inpatient admission or 391 death. A higher percentage of 6B.2-infected patients required oxygen, had a longer hospital stay and 392 had pneumonia. After adjusting and weighting for age, gender, comorbidities, obesity, vaccine status, 393 human exposure and travel history, people infected with 6B.2 still had a higher odds ratio of pneumonia 394 (Table 3 ). The data indicate that infection with clade 6B.2 viruses is associated with a higher disease 395 severity at our surveillance sites independent of patient demographics and comorbidities. The lack of 396 clade 6B.2 infections in Baltimore coupled with the large number present in Taipei is likely one of the 397 reasons that the influenza season is moderate in the US but severe in Taiwan. 398 399
Viral gene mutations known to be associated with transmission 400
Fifteen amino acid differences in 8 other virus open reading frames were identified between 6B.1 and 401 6B.2 viruses but none of these has been associated with increased virus pathogenicity. However, some 402 within previously known mutations affecting transmission. There are five amino acid differences on the 403 NA protein with 314 and 381 located on the enzymatic head domain. These mutations are located close 404 to two of four NA mutations identified in avian H9N2 influenza viruses which were shown to affect air-405 born transmission in chicken [40] . The M1-208 amino acid located between amino acids 207 and 209, 406 which affect H1N1pdm virus morphology and the efficiency of virus spread in vitro [41] . Effects of the 407 amino acid differences between 6B.1 and 6B.2 on pathogenicity will require to further experimental 408 confirmation but our initial experiments on human nasal epithelial cell cultures did not detect any 409 replication differences between clade 6B.1 and 6B.2 viruses (manuscript in preparation). 410
The 6B.1 viruses were separated into two genotypes, 6B.1 variant with 2 amino acid substitutions, NA-412 F74L and NS2-G22V, defining the subgroup. Patients infected with 6B.1 parental or variant had no 413 obvious different in disease outcome (Table 4 ). However, it cannot rule out that 6B.1 in other regions, 414 for example in Russia, might have substitutions in the genome which could lead to more severe 415 outcome than others. It requires further comparison of viral whole genome from the other regions. The 416 clade 6B.2 viruses also were separated into two genetic subgroups but no differences in patient 417 demographics or symptoms were identified between these subgroups. is possible that clade 6B.1 viruses were better adapted to infect and spread in humans. It has been 429 suggested that glycosylation is important for influenza A virus adaptation in humans [20] and gaining a 430 potential glycosylation site on the HA head at residue 162 may have given clade 6B.1 viruses an 431 evolutionary advantage. Clade 6B.1 viruses also encode an NS1-E125D mutation which increases NS1 432 interactions with cellular cleavage and polyadenylation factor 30 (CPSF30) [44] . The NS1-E125D 433 mutation of 6B.1 viruses has been suggested to be an important marker for virus adaption to humans 434 [6] . 435 436
Limitation of the study 437
Influenza vaccination, overall higher in the US than in Taiwan, could also affect baseline neutralization 438 antibody titers, thus leading to different magnitudes of epidemics (manuscript in preparation). 439 Furthermore, the different race distributions between our surveillance sites are difficult to adjust for in 440 this and any study conducted across different geographic regions. Finally, the identification of 4 genetic 441 subgroups reduced the power of our study to detect demographic and clinical differences in our 442 populations. Increasing surveillance and whole genome sequencing efforts could dramatically improve 443 the ability to identify novel virus variants that are causing altered disease in humans. 444 445 446
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